Lead Sponsor

Takeda

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Part I:
•Adult greater than or equal to (\>=)18 years of age or Canadian adult \>=19 years of age
•Ability to consent, as judged by the study investigator
•Diagnosis of at least one psychiatric disorder of at least 12 months duration, based on International classification of diseases (ICD)-10 codes registered in electronic health records
•Consecutive assessment for ADHD (as per routine clinical practice)
•Able to read and write in the first language of the respective country
•Part II
•Inclusion in study Part I
•Diagnosis of ADHD during Part I, according to routine diagnostic procedure and algorithms
•Anticipated availability for being followed over 9 months

•Part I:
•Diagnosis of any of the following at any time prior to signing informed consent: schizoaffective disorder, intellectual disability, or other cognitive disorders
•Occurrence of any of the following events within the 6 months prior to signing consent: psychotic episodes, acute intoxication, or psychotropic drug withdrawal syndrome.
•Diagnosis of ADHD at any time before study inclusion
•Serious and unstable medical condition (severe disease that limits survival to 1 year)
•Participation in a clinical interventional trial in the 12 months prior signing consent
•Part II:
•\- Participant being followed-up for ADHD in a different site

Related studies

NCT06810180 · Attention Deficit Hyperactivity Disorder (ADHD), Sleep, and more

NCT07189442 · Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD)

NCT07180758 · Attention Deficit Hyperactivity Disorder (ADHD)

NCT07459699 · Attention Deficit Hyperactivity Disorder (ADHD)

NCT07165509 · Down Syndrome, Autism Spectrum Disorder, and more

A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions and Their Quality of Life